Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound — is officially over.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
FDA Approves Zepbound for Obstructive Sleep Apnea
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
KSL1d
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
Zepbound and Lilly's widely used diabetes drug, Mounjaro, both chemically called tirzepatide, belong to a class of drugs ...
rheumatologyadvisor16d
Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
ABC News20d
Zepbound users discuss weight loss after preliminary research touts effectiveness
Zepbound is a medication containing tirzepatide, which the preliminary study showed to be more effective for weight loss than Wegovy, which contains semaglutide. This preliminary study ...
Yahoo16d
Is Zepbound or Wegovy Better for Weight Loss? One Can Help You Shed 50 Lbs
Zepbound (tirzepatide) and Wegovy (semaglutide) both support weight loss by targeting hormones that influence appetite and metabolism. However, their mechanisms differ significantly. Wegovy ...